An update on the effects of debulking surgery and liver directed intra-arterial therapies on quality of life in patients with metastatic neuroendocrine tumours

2021 ◽  
Author(s):  
Eleanor Woods ◽  
Adam Sinclair ◽  
Emma Jarvis ◽  
Emma Ramsey ◽  
Lulu Tanno ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Neuroendocrine Tumours ◽  
Debulking Surgery

scholarly journals Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours

2021 ◽  
Author(s):  
Håkan Ohlsson ◽  
Gideon Wahlberg ◽  
Marlene Malmquist ◽  
Rita Gustafsson ◽  
Anna Sundlöv ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Neuroendocrine Tumours ◽  
Bowel Function ◽  
Charlson Comorbidity Index Score ◽  
Bowel Symptoms ◽  
Hrqol Questionnaire ◽  
Related Quality ◽  
Eortc Qlq ◽  
Midgut Net

Abstract Introduction Patients with midgut neuroendocrine tumours (NETs) suffer from decreased health-related quality of life (HRQoL), in large part due to bowel symptoms. However, it is unknown which bowel symptoms affect HRQoL the most. An enhanced understanding of this is essential to better focus treatment on this aspect of the disease. This study aimed to determine which bowel symptoms affect HRQoL the most in patients with midgut NETs. Methods Consenting patients with midgut NET completed the Memorial Sloan Kettering Bowel Function Instrument and the HRQoL questionnaire (EORTC QLQ-C30). The correlation between bowel symptoms and HRQoL was analysed using multiple linear regression, adjusting for age, Charlson Comorbidity Index score, presence of metastatic disease, chromogranin A, and BMI yielding ß-coefficients with 95% confidence intervals. Results Totally, 119 patients with midgut NET completed the questionnaires and were included in the study. Loose stool and bowel frequency ≥ 3/day were the most common bowel symptoms, reported by 47% and 56% of patients, respectively. However, sensitivity to certain types of food and beverages, a feeling of incomplete emptying of the bowel, and soiling were the symptoms most strongly correlated with decreased HRQoL, especially within domains concerning role and social function, with ß-coefficients for the strongest correlated symptoms of 15.0 and 14.6, respectively. Discussion While symptoms concerning stool consistency and frequency are common in patients with midgut NET, our study suggests that other, more socially stigmatising symptoms affect patients’ HRQoL more. Our findings could help caregivers understand patients’ perceptions of the disease and provide avenues for more directed therapies.

scholarly journals Neuroendocrine tumours: what gastroenterologists need to know

2020 ◽  
pp. flgastro-2020-101431
Author(s):  
Mohid S Khan ◽  
D Mark Pritchard
Keyword(s):  
Quality Of Life ◽  
Neuroendocrine Tumours ◽  
Comprehensive Evaluation ◽  
Treatment Options ◽  
Somatostatin Analogue ◽  
Low Grade ◽  
Multiple Treatment ◽  
Gastrointestinal Problems ◽  
Patient Reported

Gastroenterologists are intermittently involved in diagnosing and managing patients who have neuroendocrine tumours (NETs). However, few UK gastroenterologists have received extensive training about this topic. This article aims to provide a brief introduction to NETs; it is aimed at a general gastroenterologist audience.NETs present in diverse ways and many symptomatic patients unfortunately experience significant delays in diagnosis. Comprehensive evaluation of a patient with a possible NET involves assessing their symptoms, the tumour’s primary organ of origin, its differentiation status, grade and stage, whether the NET is secreting hormones and whether there is any underlying hereditary predisposition. Such assessment often needs specialist investigations such as nuclear medicine scans. All these factors influence patient management and prognosis, so a patient’s case and investigations should always be discussed by a fully constituted NET multidisciplinary team. Most localised tumours are considered for resection, but there are multiple treatment options for metastatic disease and many patients receive several different therapies during the course of their illness. The most common first line treatment in patients who have metastatic low grade NETs is monthly long acting somatostatin analogue injections. Prognosis is highly variable, but some patients who have inoperable metastases survive for many years on treatment with good quality of life. Gastroenterologists may also be involved in managing the non-tumour associated chronic gastrointestinal problems that some patients experience. Their involvement has been shown to improve patient-reported outcomes and quality of life.

scholarly journals Role of high dose octreotide LAR for the treatment of GEP-NETs

2009 ◽  
Vol 3 (1) ◽  
pp. 7-14
Author(s):  
Giulia M. Franchi ◽  
Chiara Cappelletti ◽  
Valentina V. Villa ◽  
Emanuele Bosi ◽  
Marco F. Manzoni
Keyword(s):  
Quality Of Life ◽  
Tumour Growth ◽  
Neuroendocrine Tumours ◽  
Clinical Symptoms ◽  
Standard Dose ◽  
Diagnostic Tools ◽  
High Dose ◽  
Octreotide Lar

Neuroendocrine Tumours (NETs) are a heterogeneous group of rare neoplasms that account for 0,5% of all malignancies. The increased incidence observed in the last few decades may be accounted for by increased awareness, improved diagnostic tools and a revision in the definition. The main primary sites are the gastro-entero-pancreatic (GEP) tract (62-67%), and the lung (22-27%). In patients with GEP-NETs, the strongest predictor of 5-years survival is the staging. An adequate clinical management of GEP-NETs should be multidisciplinary and should aim at assuring a good quality of life. Somatostatin (sst) analogues are widely used in these tumours, which often express sst receptors, since they are demonstrated to reduce clinical symptoms and tumour growth. Herein we explore the usefulness of doubling octreotide LAR dose in selected patients after escaping from symptoms control and/or tumour stabilization in course of treatment with standard dose.

scholarly journals Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa

2020 ◽  
Vol 4 ◽  
Author(s):  
Daleen Geldenhuys ◽  
Bernardo L. Rapoport ◽  
Samuel Fourie ◽  
Waldemar M. Szpak ◽  
Sylvia Rodrigues ◽  
...  
Keyword(s):  
Quality Of Life ◽  
South Africa ◽  
Neuroendocrine Tumours ◽  
Grade 5 ◽  
Level Of Satisfaction ◽  
Number Of Patients ◽  
Grade 3 ◽  
Gastroenteropancreatic Neuroendocrine Tumours ◽  
Lanreotide Autogel

Background: Neuroendocrine tumours are known to impact patients’ quality of life because of the symptoms caused by hypersecretion of serotonin and other peptides, in particular diarrhoea and flushing.Aim: The Q-SYMTU study was a prospective, observational registry that included 24 symptomatic patients with gastroenteropancreatic neuroendocrine tumours.Setting: Multiple oncology practices in South Africa.Method: Patients’ level of satisfaction was evaluated for a 6-month period from initiation of treatment with lanreotide Autogel.Results: The number of patients who had greater than 50% self-reported reduction in daily episodes of diarrhoea and flushing were 67% and 80%, respectively, over a 6-month period.Conclusion: Treatment with lanreotide Autogel was generally well tolerated, as demonstrated by low occurrence of Grade 3 and Grade 4 adverse events (AEs). None of the Grade 4 AEs were related to the study treatment. No Grade 5 AEs were reported.

Sign in / Sign up

Export Citation Format

Share Document